ANI Pharmaceuticals (ANIP) Set to Announce Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) will post its quarterly earnings results before the market opens on Friday, May 10th. Analysts expect ANI Pharmaceuticals to post earnings of $0.98 per share for the quarter. ANI Pharmaceuticals has set its FY24 guidance at $4.26-4.67 EPS and its FY 2024 guidance at 4.260-4.670 EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The company had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $65.62 on Thursday. ANI Pharmaceuticals has a fifty-two week low of $38.91 and a fifty-two week high of $70.81. The business has a 50-day moving average of $66.96 and a two-hundred day moving average of $59.36. The stock has a market capitalization of $1.38 billion, a P/E ratio of 78.12 and a beta of 0.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81.

Insider Activity at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 10,093 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $65.35, for a total transaction of $659,577.55. Following the transaction, the chief operating officer now directly owns 872,527 shares in the company, valued at $57,019,639.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Nikhil Lalwani sold 28,965 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total value of $1,897,786.80. Following the sale, the chief executive officer now directly owns 444,981 shares in the company, valued at approximately $29,155,155.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Muthusamy Shanmugam sold 10,093 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $65.35, for a total value of $659,577.55. Following the completion of the sale, the chief operating officer now owns 872,527 shares in the company, valued at $57,019,639.45. The disclosure for this sale can be found here. Insiders have sold 176,803 shares of company stock worth $11,695,866 over the last three months. Company insiders own 12.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Capital One Financial assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Guggenheim reissued a “buy” rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. HC Wainwright boosted their price objective on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Finally, Truist Financial boosted their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $80.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.